
News|Articles|May 1, 2002
Public Citizen requests bans on Arava, Meridia
From Consumer Advocy Groups:Public Citizen urges ban on Arava. . . According to Public Citizen, 130 cases of severe liver toxicity-including 56 hospitalizations and 12 deaths-have been reported to the FDA since the 1998 introduction of rheumatoid arthritis agent leflunomide (Arava). This equates to six times the number of cases of fatal liver toxicity seen with methotrexate, although 5.5 times more prescriptions for methotrexate were filled over the 3-year comparative period. Public Citizen also says that leflunomide has been associated with 12 cases of Stevens-Johnson syndrome (compared with none reported with methotrexate) and more reports of lymphoma and hypertension.
Advertisement
Advertisement
Related Content
Advertisement





FDA approves first biosimilars interchangeable with Simponi/Simponi Aria
Published: | Updated:
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends
4
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
5






















